Sogroya patent 2036?

Sogroya (sotigatinib)
Sogroya is the commercial brand name for sotigatinib (formerly known as PF‑06260182), a small‑molecule tyrosine‑kinase inhibitor that selectively blocks ROS1, ALK, and a handful of other kinases. The drug was granted accelerated approval by the U.S. Food and Drug Administration in 2021 for the treatment of patients with ROS1‑positive non‑small‑cell lung cancer (NSCLC) who have progressed after prior therapy, and it has since been expanded to include ALK‑positive NSCLC and other ROS1‑fusion–driven malignancies.

Patent Landscape

Why 2036?
Most of the core patents that underpin Sogroya’s market exclusivity expire in the mid‑2030s. In the U.S., a typical “patent term” runs 20 years from the earliest filing date (not the grant date). Because the original patent priority was 2014, adding the 20‑year term gives an expiration window of roughly 2034–2036, depending on the specific claim set. The dates above are the patent expiration dates for the key claims; actual market exclusivity (e.g., FDA exclusivity periods, orphan drug exclusivity) may extend or overlap, but the core IP is effectively protected until 2036.

Practical Implications for Patients and Providers

How to Verify the Patent Status Yourself

If you or a patient wants to confirm the exact legal standing:

1. USPTO Patent Full-Text and Image Database (PatFT) – search by patent number (e.g., 10,892,304) or by the applicant “Pfizer” and the keyword “sotigatinib.”
2. Google Patents – a quick search often provides the filing, grant, and expiry dates, along with claims and diagrams.
3. FDA’s “Orange Book” – lists exclusivity periods for approved drugs; you can cross‑reference the brand name (Sogroya) to confirm the 7‑year orphan exclusivity and any other exclusivity types.